XML 27 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Condensed Consolidated Balance Sheets (USD $)
Jun. 30, 2014
Dec. 31, 2013
Current assets:    
Cash and cash equivalents $ 55,499,000 $ 60,009,000
Marketable securities 14,997,000 39,994,000
Prepaid expenses and other current assets 3,331,000 4,387,000
Total current assets 73,827,000 104,390,000
Property and equipment, net 609,000 626,000
Restricted cash 125,000 125,000
Other non-current assets 12,000 12,000
Total assets 74,573,000 105,153,000
Current liabilities :    
Accounts payable 5,027,000 3,710,000
Accrued expenses and other current liabilities 6,464,000 5,820,000
Warrant liability 1,000 20,000
Deferred revenue 455,000 788,000
Total current liabilities 11,947,000 10,338,000
Deferred revenue, non-current 13,682,000 13,909,000
Other 2,000 6,000
Total liabilities 25,631,000 24,253,000
Commitments and contingencies      
Stockholders' equity:    
Preferred stock, $0.01 par value, 5,000,000 authorized at June 30, 2014 and December 31, 2013, none issued and outstanding at June 30, 2014 and December 31, 2013      
Common stock, $0.01 par value, 75,000,000 authorized at June 30, 2014 and December 31, 2013, 21,673,486 and 21,467,482 shares issued and outstanding at June 30, 2014 and December 31 2013 217,000 215,000
Additional paid in capital 314,630,000 311,093,000
Accumulated other comprehensive income   1,000
Accumulated deficit (266,328,000) (230,896,000)
Total Onconova Therapeutics, Inc. stockholders' equity 48,519,000 80,413,000
Non-controlling interest 423,000 487,000
Total stockholders' equity 48,942,000 80,900,000
Total liabilities and stockholders' equity $ 74,573,000 $ 105,153,000